Pay in 4 interest-free payments of $5.57 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
The SURPASS-CVOT trial, where dulaglutide at the dose of 1.5 mg/week or at the highest tolerated dose, is the comparator, has a distinctive design from the other trials: the primary endpoint is the time to the first manifestation of any major adverse CV event (MACE), defined as myocardial infarction, stroke or CV death
And long-term safety studies in humans would address the most significant remaining uncertainty about the compound
Brands cannot simply message their way out of muted appetite
It works by disrupting the FOXO4-p53 protein interaction that protects senescent cells from apoptosis
Phase 2 trial (NEJM 2023) reported 24.2% mean weight loss at 48 weeks with 12 mg/week retatrutide, with gastrointestinal adverse events rising sharply at the 8 mg and 12 mg doses
US$ 22.04
US$ 24.24
US$ 28.08
US$ 28.85
US$ 28.86
US$ 29.04
US$ 20.41
